Efficacy and Tolerability of Paroxetine for the Long-Term Treatment of Generalized Anxiety Disorder
J Clin Psychiatry 2003;64(3):250-258
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: Paroxetine has demonstrated efficacy
in depression and anxiety disorders, including generalized
anxiety disorder (GAD). This 32-week study evaluated the
maintained efficacy and safety of paroxetine in GAD by assessing
the potential for relapse after discontinuation of medication.
Method: Adults (N = 652) with DSM-IV GAD and a
Clinical Global Impressions-Severity of Illness (CGI-S) score
>= 4 received paroxetine (20-50 mg/day) for 8 weeks. Patients
whose CGI-S score had decreased by at least 2 points to <= 3
at week 8 were randomly assigned to double-blind treatment with
paroxetine (N = 278) or placebo (N = 288) for a further 24 weeks.
The primary efficacy parameter was the proportion of patients
relapsing (an increase in CGI-S score of at least 2 points to a
score >= 4 or withdrawal resulting from lack of efficacy)
during double-blind treatment.
Results: Significantly fewer paroxetine than
placebo patients relapsed during the 24-week double-blind phase
(10.9% vs. 39.9%; p < .001). Placebo patients were almost 5
times more likely to relapse than paroxetine patients (estimated
hazard ratio = 0.213 [95% CI = 0.1 to 0.3]; p < .001).
Statistical significance in favor of paroxetine was demonstrated
for all secondary efficacy parameters, including functional
status. Twice as many paroxetine patients as placebo patients
(73%) achieved remission. Paroxetine was well tolerated, with no
unexpected adverse events reported.
Conclusion: Paroxetine was found to be effective
and well tolerated for both the short- and long-term treatment of
DSM-IV GAD. Continued treatment with paroxetine significantly
reduced the potential for relapse of GAD symptoms.